CEL-SCI Corporation (NYSE MKT: CVM) today reported financial results for the quarter ended December 31, 2014.
Key corporate and clinical developments during Q1 fiscal year 2015 include:
•Enrolled an additional 63 patients with advanced primary, not yet treated, head and neck cancer into the global pivotal Phase III trial. As of January 31, 2015, 352 patients have been enrolled in the study.
Help employers find you! Check out all the jobs and post your resume.
